IOL Chemicals PAT Flat Despite Revenue Growth; Declares Interim Dividend

OTHER
Whalesbook Logo
AuthorAbhay Singh|Published at:
IOL Chemicals PAT Flat Despite Revenue Growth; Declares Interim Dividend
Overview

IOL Chemicals and Pharmaceuticals reported a 10.91% YoY revenue increase to ₹580.39 Cr in Q3 FY26. However, consolidated Profit After Tax (PAT) remained nearly flat at ₹20.58 Cr due to an exceptional item of ₹11.21 Cr related to new Labour Codes. The company declared an interim dividend of ₹1 per share. The pharmaceutical segment showed robust growth, outpacing the chemical segment.

📉 The Financial Deep Dive

IOL Chemicals and Pharmaceuticals Limited (IOLCP) has unveiled its un-audited financial results for the third quarter and nine months ended December 31, 2025 (Q3 FY26), revealing a mixed performance. While top-line revenue demonstrated healthy expansion, bottom-line profitability faced headwinds, largely due to an exceptional item.

The Numbers:

  • Consolidated Revenue: ₹580.39 Cr in Q3 FY26, marking a significant 10.91% increase year-on-year (YoY) from ₹523.30 Cr in Q3 FY25. For the nine-month period ended December 31, 2025, revenue grew 9.55% YoY to ₹1,699.61 Cr.
  • Consolidated Profit After Tax (PAT): The company reported PAT of ₹20.58 Cr for Q3 FY26, which was nearly flat compared to ₹20.55 Cr in the prior year. This indicates margin compression as revenue grew faster than profit.
  • Profit Before Tax (PBT): PBT also saw minimal movement, standing at ₹27.55 Cr in Q3 FY26 versus ₹27.80 Cr YoY.
  • Earnings Per Share (EPS): Basic and Diluted EPS for Q3 FY26 stood at ₹0.70, flat YoY. This is a decrease from ₹1.02 in the previous quarter (Q2 FY26).
  • For the nine-month period, PAT increased 21.30% YoY to ₹84.48 Cr, with EPS rising from ₹2.37 to ₹2.88 YoY.

The Quality:
The PAT margin for Q3 FY26 contracted to approximately 3.54% (₹20.58 Cr / ₹580.39 Cr) from about 3.93% (₹20.55 Cr / ₹523.30 Cr) in Q3 FY25, reflecting pressure on profitability despite revenue gains. A significant factor contributing to the flat PAT was an exceptional item of ₹11.21 Cr. This charge primarily arose from changes in wage definition due to the notification of the four Labour Codes by the Government of India, impacting the period's profit. The company did not provide detailed cash flow statements or working capital movements in this release.

Segment Performance:

  • The Pharmaceutical segment was a growth driver, registering a 18.45% YoY revenue increase to ₹356.05 Cr in Q3 FY26.
  • The Chemical segment recorded a more modest 4.61% YoY growth, with revenue at ₹287.82 Cr.

Corporate Actions & Outlook:
The Board of Directors declared an interim dividend of ₹1/- (50%) per equity share for FY25-26, providing a direct return to shareholders. In terms of strategic restructuring, the company is proceeding with the closure of its wholly-owned subsidiary, IOL Life Sciences Limited, by way of striking off its name. Concurrently, an overseas subsidiary, IOL Pharmaxis UK Limited, was incorporated in the United Kingdom, although its business operations have not yet commenced.

🚩 Risks & Outlook
Investors will be watching how IOLCP navigates the margin pressures evident in Q3 FY26, especially as the impact of the exceptional item related to wage code implementation is factored in. The differing growth rates between the Pharmaceutical and Chemical segments will also be a key area to monitor. The successful integration and future performance of the newly incorporated UK subsidiary, alongside the strategic rationale behind closing the domestic subsidiary, will shape the company's long-term direction.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.